The Vildagliptin Experience — 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration

The discovery of the incretin hormone glucagon like peptide-1 (GLP-1), and its usefulness in the treatment of type 2 diabetes mellitus (T2DM) followed by the finding that dipeptidyl peptidase-4 (DPP-4) inhibition prevents GLP-1 inactivation, led to the discovery of DPP-728. In 1999, studies with DPP...

Descripción completa

Detalles Bibliográficos
Autores principales: Foley, James E, Ahrén, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Touch Medical Media 2017
Materias:
Type 2 Diabetes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813465/
https://www.ncbi.nlm.nih.gov/pubmed/29632608
http://dx.doi.org/10.17925/EE.2017.13.02.56

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813465/
https://www.ncbi.nlm.nih.gov/pubmed/29632608
http://dx.doi.org/10.17925/EE.2017.13.02.56

Ejemplares similares